Search Results

You are looking at 1 - 2 of 2 items for

  • Author: George Ansstas x
Clear All Modify Search
Full access

Tanner M. Johanns, George Ansstas and Sonika Dahiya

Full access

Tanner M. Johanns, Cole J. Ferguson, Patrick M. Grierson, Sonika Dahiya and George Ansstas

BRAF V600E mutations have been successfully treated with targeted therapy in melanoma, non–small cell lung cancer, and thyroid cancer. Interestingly, these mutations have also been identified in a subset of pediatric and adult brain tumors, with several cases reportedly responding to targeted therapy. However, these reports have been limited to single-agent BRAF inhibitor therapy and recurrent disease. Herein, we report dramatic clinical and radiographic responses to combination dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in 2 adults with high-grade gliomas (HGGs), with 1 patient treated in the first-line setting. These observations, together with prior case reports, advocate for routine screening of BRAF point mutations in adult HGGs, and suggest that treatment with dual-targeted therapy, even in newly diagnosed cases, is safe and effective.